Expertise in
10
conditions

Dr. Richard A. Aplenc

Hematology | Oncology
Office
3401 Civic Center Blvd, 
Philadelphia, PA 
30 Years of Experience
Expertise in
10
conditions
Office
3401 Civic Center Blvd, 
Philadelphia, PA 

Overview

Richard Aplenc is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. He has been practicing medicine for over 30 years.

Dr. Aplenc is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Childhood Acute Myeloid Leukemia, Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 248 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatrics in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
3401 Civic Center Blvd, Philadelphia, PA 19104
Other Locations
Office
3500 Civic Center Blvd, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Aplenc has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2026
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2026
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: October 15, 2025
Intervention Type: Biological
Study Drugs: CART123 cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drug: CD33-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Enrollment Status: Completed
Publish Date: August 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

248 Total Publications

Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.
Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 24, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Referral may be required

Office

3500 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-3025
Languages Spoken:
English

John Maris is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Maris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Rhabdomyosarcoma.

Expertise in
17
conditions
Dr. Stephan A. Grupp
Hematology | Oncology
Expertise in
17
conditions
Dr. Stephan A. Grupp
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Stephan Grupp is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Grupp is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Richard A. Aplenc

How do I make an appointment with Dr. Richard A. Aplenc?

You can book an appointment with Dr. Richard A. Aplenc by calling their office at 215-590-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Richard A. Aplenc a top-rated expert for Childhood Acute Myeloid Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Richard A. Aplenc is classified as an Elite expert for Childhood Acute Myeloid Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Richard A. Aplenc specialize in?

While Dr. Richard A. Aplenc is a Hematology, they have specific expertise in Childhood Acute Myeloid Leukemia, Leukemia, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Richard A. Aplenc participate in research or clinical trials?

Yes. Dr. Richard A. Aplenc has published 248 articles and abstracts on conditions like Childhood Acute Myeloid Leukemia. You can view a list of Dr. Richard A. Aplenc's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Richard A. Aplenc accept my insurance?

Dr. Richard A. Aplenc accepts most major insurance plans, including Highmark and Horizon Healthcare. We recommend calling the office directly at 215-590-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aplenc's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile